GlassScriptPhysician profile
Ismael Diaz
NPI 1831187004
$10,257.02
in general payments reported to CMS, 2019-2025
57 companies · $1,964 in 2025
The $1,964 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,475 · 2020: $942 · 2021: $1,976 · 2022: $1,288 · 2023: $1,174 · 2024: $1,438 · 2025: $1,964.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,576.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,645.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,325.78 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Biohaven Pharmaceuticals, INC. | $1,229.54 | 2021 | |
| Lilly USA, LLC | $706.36 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $614.12 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $584.30 | 2020-2025 | |
| Merz North America, INC. | $451.91 | 2022-2023 | Xeomin |
| Abbvie INC. | $364.99 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.84 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Glaxosmithkline, LLC. | $230.08 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Inspire Medical Systems, INC. | $212.87 | 2024-2025 | Inspire |
| Allergan, INC. | $201.36 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $188.32 | 2019-2023 | Xarelto |
| Pfizer INC. | $171.00 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $170.02 | 2019-2022 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ismael Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.